| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Full Paper |
Tumour Microcirculation Group, Gray Cancer Institute, PO Box 100, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR, UK
The tumour vasculature is an attractive target for therapy because of its accessibility to blood-borne anticancer agents and the reliance of most tumour cells on an intact vascular supply for their survival. For convenience, therapeutic targeting of the tumour vasculature can be divided into antiangiogenic approaches, which target the process of new blood vessel development and antivascular approaches, which target the established tumour vasculature. Many agents are now in clinical trial for the treatment of cancer by these methods. The main aim of this article is to describe the vascular effects of some of these agents and identify suitable end-points for measuring efficacy in early clinical trials. For drugs which are active below their maximum tolerated dose (MTD), measurement of vascular end-points is required to determine the most effective dosing/scheduling protocols. In addition, many of the current and developing antiangiogenic agents have additional mechanisms of action unrelated to angiogenesis per se, requiring measurement of vascular end-points to understand their mechanisms of action. Measurement of tumour microvascular density (MVD) from tumour biopsies is a common method for assessing the efficacy of antiangiogenic drugs. The limitations of this method and alternative end-points, which take into account vascular function, are discussed. Pre-clinical data regarding tumour response to the antivascular agent combretastatin A-4 3-0-phosphate (CA-4-P) are discussed in the context of guiding clinical trial planning. Finally, the accessibility of vascular end-points for clinical imaging is addressed.
This article has been cited by other articles:
 |
|
 |
|
  B. Kotz, C. West, A. Saleem, T. Jones, and P. Price Blood flow and Vd (water): both biomarkers required for interpreting the effects of vascular targeting agents on tumor and normal tissue Mol. Cancer Ther., February 1, 2009; 8(2): 303 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Goh, S. Halligan, and C. I. Bartram Quantitative Tumor Perfusion Assessment with Multidetector CT: Are Measurements from Two Commercial Software Packages Interchangeable? Radiology, March 1, 2007; 242(3): 777 - 782. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Iga, S. Sarkar, K. M. Sales, M. C. Winslet, and A. M. Seifalian Quantitating Therapeutic Disruption of Tumor Blood Flow with Intravital Video Microscopy Cancer Res., December 15, 2006; 66(24): 11517 - 11519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. S. Ng, V. Goh, E. Klotz, H. Fichte, M. I. Saunders, P. J. Hoskin, and A. R. Padhani Quantitative Assessment of Lung Cancer Perfusion Using MDCT: Does Measurement Reproducibility Improve with Greater Tumor Volume Coverage? Am. J. Roentgenol., October 1, 2006; 187(4): 1079 - 1084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Goh, S Halligan, L Gartner, P Bassett, and C I Bartram Quantitative colorectal cancer perfusion measurement by multidetector-row CT: does greater tumour coverage improve measurement reproducibility? Br. J. Radiol., July 1, 2006; 79(943): 578 - 583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Goh, S. Halligan, J.-A. Hugill, and C. I. Bartram Quantitative assessment of tissue perfusion using MDCT: comparison of colorectal cancer and skeletal muscle measurement reproducibility. Am. J. Roentgenol., July 1, 2006; 187(1): 164 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N Raghunand, R A Gatenby, and R J Gillies Microenvironmental and cellular consequences of altered blood flow in tumours Br. J. Radiol., December 1, 2003; 76(suppl_1): S11 - S22. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| BJR | DMFR | IMAGING | ALL BIR JOURNALS |
